For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260112:nRSL4115Oa&default-theme=true
RNS Number : 4115O CVS Group plc 12 January 2026
12 January 2026
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that on 09 January 2026 it purchased the following number of its
ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg,
Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the
terms of the share buyback programme announced on 24 October 2025 (the "Share
Buyback Programme").
Date of purchase: 09/01/2026
Aggregate number of Ordinary Shares purchased: 30,119
Lowest price paid per share (GBp): 1,324.00
Highest price paid per share (GBp): 1,360.00
Volume weighted average price paid per share (GBp): 1,344.63
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary
Shares purchased, CVS will have 70,551,512 Ordinary Shares in issue and holds
no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 70,551,512 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has
repurchased 1,189,271 Ordinary Shares in aggregate at a weighted average price
of 1,231.92 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, the table below contains detailed
information of the individual trades made by Berenberg as part of the Share
Buyback Programme.
Individual transactions:
Number of Transaction price (GBp share) Time of Transaction Trading Venue
Ordinary Shares purchased transaction (UK Time) reference number
231 1324 09/01/2026 08:08:13 1367544040526662 XLON
66 1324 09/01/2026 08:09:54 1367544040527466 XLON
553 1330 09/01/2026 08:12:24 1367544040527993 XLON
600 1330 09/01/2026 08:19:13 1367544040529841 XLON
387 1330 09/01/2026 08:27:43 1367544040531501 XLON
49 1330 09/01/2026 08:27:43 1367544040531502 XLON
320 1330 09/01/2026 08:27:44 1367544040531519 XLON
797 1338 09/01/2026 08:52:39 1367544040534919 XLON
1390 1338 09/01/2026 08:52:47 1367544040534928 XLON
1390 1338 09/01/2026 08:58:18 1367544040535665 XLON
725 1338 09/01/2026 08:59:31 1367544040535843 XLON
148 1340 09/01/2026 09:04:38 1367544040537216 XLON
1158 1338 09/01/2026 09:20:21 1367544040539210 XLON
180 1338 09/01/2026 09:20:21 1367544040539212 XLON
66 1336 09/01/2026 09:27:21 1367544040540037 XLON
4 1336 09/01/2026 10:05:18 1367544040545512 XLON
356 1336 09/01/2026 10:07:20 1367544040545755 XLON
424 1334 09/01/2026 10:07:20 1367544040545769 XLON
121 1334 09/01/2026 10:07:26 1367544040545779 XLON
9 1334 09/01/2026 10:07:26 1367544040545780 XLON
260 1338 09/01/2026 11:01:15 1367544040551733 XLON
66 1338 09/01/2026 11:02:45 1367544040551861 XLON
823 1336 09/01/2026 11:11:07 1367544040552555 XLON
204 1334 09/01/2026 11:14:33 1367544040552735 XLON
190 1334 09/01/2026 11:14:33 1367544040552736 XLON
141 1332 09/01/2026 11:18:00 1367544040552913 XLON
154 1328 09/01/2026 11:32:45 1367544040553839 XLON
159 1334 09/01/2026 12:02:04 1367544040555609 XLON
84 1332 09/01/2026 12:13:33 1367544040557112 XLON
66 1332 09/01/2026 12:18:03 1367544040557569 XLON
125 1332 09/01/2026 12:18:04 1367544040557570 XLON
242 1336 09/01/2026 12:29:55 1367544040558491 XLON
1272 1340 09/01/2026 12:36:08 1367544040559021 XLON
700 1348 09/01/2026 13:07:35 1367544040562181 XLON
200 1348 09/01/2026 13:07:35 1367544040562187 XLON
847 1348 09/01/2026 13:10:54 1367544040562540 XLON
351 1348 09/01/2026 13:10:54 1367544040562541 XLON
1185 1348 09/01/2026 13:22:08 1367544040563729 XLON
895 1350 09/01/2026 13:36:22 1367544040565981 XLON
430 1350 09/01/2026 13:45:38 1367544040567100 XLON
150 1350 09/01/2026 13:45:38 1367544040567101 XLON
10000 1350 09/01/2026 13:49:16 1367544040567707 XLON
100 1360 09/01/2026 15:50:22 1367544040590331 XLON
214 1360 09/01/2026 16:03:38 1367544040592690 XLON
683 1360 09/01/2026 16:03:38 1367544040592693 XLON
186 1360 09/01/2026 16:03:38 1367544040592689 XLON
186 1360 09/01/2026 16:03:38 1367544040592694 XLON
12 1360 09/01/2026 16:03:38 1367544040592695 XLON
174 1360 09/01/2026 16:03:38 1367544040592696 XLON
186 1360 09/01/2026 16:03:38 1367544040592697 XLON
186 1360 09/01/2026 16:03:38 1367544040592698 XLON
186 1360 09/01/2026 16:03:38 1367544040592699 XLON
186 1360 09/01/2026 16:03:38 1367544040592700 XLON
186 1360 09/01/2026 16:03:38 1367544040592701 XLON
116 1360 09/01/2026 16:05:17 1367544040592928 XLON
Contacts
CVS Group
plc
via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Peel Hunt LLP (Nominated Adviser & Joint Broker)
+44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Berenberg (Joint
Broker)
+44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Camarco (Financial PR)
cvsg@camarco.co.uk
Ginny
Pulbrook
+44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia. CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSUPUMGGUPQGRB
Copyright 2019 Regulatory News Service, all rights reserved